ID
41354
Beschreibung
Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 This Form has to be filled in during the Treatment period after Circuit Prime is administered and whenever a Bolus of Argatroban is administered. Continuous infusions are recorded in a separate form.
Link
https://clinicaltrials.gov/ct2/show/NCT00039858
Stichworte
Versionen (1)
- 03/09/2020 03/09/2020 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
3 septembre 2020
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858
Dosing Information - Circuit Prime and Bolus
- StudyEvent: ODM
Beschreibung
Dosing Information - Circuit Prime
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C1533716
- UMLS CUI-3
- C3805286
Beschreibung
*Protocol violation
Datentyp
text
Alias
- UMLS CUI [1]
- C3805286
Beschreibung
Part to be filled in: μg **Recommend 50μg/750mL
Datentyp
integer
Maßeinheiten
- μg
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C3805286
Beschreibung
Part to be filled in: mL **Recommend 50μg/750mL
Datentyp
integer
Maßeinheiten
- mL
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C3805286
Beschreibung
Dosing Information - Bolus
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C1533716
- UMLS CUI-3
- C1511237
Beschreibung
Number of bolus administered
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C2348184
Beschreibung
Please fill in for all nine bolus numbers.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1521801
Beschreibung
Bolus dose
Datentyp
integer
Maßeinheiten
- mcg/kg
Alias
- UMLS CUI [1]
- C1511237
Beschreibung
(dd-mmm-yyyy)
Datentyp
date
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C0808070
Beschreibung
(0000-2359)
Datentyp
time
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1301880
Beschreibung
(0000-2359)
Datentyp
time
Alias
- UMLS CUI [1,1]
- C1511237
- UMLS CUI [1,2]
- C1522314
Ähnliche Modelle
Dosing Information - Circuit Prime and Bolus
- StudyEvent: ODM
C0019994 (UMLS CUI [1,2])
C2348184 (UMLS CUI [1,2])
C1533716 (UMLS CUI-2)
C3805286 (UMLS CUI-3)
C0304229 (UMLS CUI [1,2])
C3805286 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,2])
C3805286 (UMLS CUI [1,3])
C1533716 (UMLS CUI-2)
C1511237 (UMLS CUI-3)
C2348184 (UMLS CUI [1,2])
C1521801 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,2])
C1522314 (UMLS CUI [1,2])
Keine Kommentare